Stock Research for SUPN

SUPN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SUPN Stock Chart & Research Data

The SUPN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SUPN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SUPN Due diligence Resources & Stock Charts

The SUPN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SUPN Detailed Price Forecast - CNN Money CNN View SUPN Detailed Summary - Google Finance
Yahoo View SUPN Detailed Summary - Yahoo! Finance Zacks View SUPN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View SUPN Trends & Analysis - Trade-Ideas Barrons View SUPN Major Holders - Barrons
NASDAQ View SUPN Call Transcripts - NASDAQ Seeking View SUPN Breaking News & Analysis - Seeking Alpha
Spotlight View SUPN Annual Report - CompanySpotlight.com OTC Report View SUPN OTC Short Report - OTCShortReport.com
TradeKing View SUPN Fundamentals - TradeKing Charts View SUPN SEC Filings - Bar Chart
WSJ View Historical Prices for SUPN - The WSJ Morningstar View Performance/Total Return for SUPN - Morningstar
MarketWatch View the Analyst Estimates for SUPN - MarketWatch CNBC View the Earnings History for SUPN - CNBC
StockMarketWatch View the SUPN Earnings - StockMarketWatch MacroAxis View SUPN Buy or Sell Recommendations - MacroAxis
Bullish View the SUPN Bullish Patterns - American Bulls Short Pains View SUPN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View SUPN Stock Mentions - StockTwits PennyStocks View SUPN Stock Mentions - PennyStockTweets
Twitter View SUPN Stock Mentions - Twitter Invest Hub View SUPN Investment Forum News - Investor Hub
Yahoo View SUPN Stock Mentions - Yahoo! Message Board Seeking Alpha View SUPN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for SUPN - SECform4.com Insider Cow View Insider Transactions for SUPN - Insider Cow
CNBC View SUPN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SUPN - OTC Markets
Yahoo View Insider Transactions for SUPN - Yahoo! Finance NASDAQ View Institutional Holdings for SUPN - NASDAQ


Stock Charts

FinViz View SUPN Stock Insight & Charts - FinViz.com StockCharts View SUPN Investment Charts - StockCharts.com
BarChart View SUPN Stock Overview & Charts - BarChart Trading View View SUPN User Generated Charts - Trading View




Latest Financial News for SUPN


Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Posted on Wednesday April 24, 2024

ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and business results for the first quarter of 2024 after the market closes on Wednesday, May 8, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to p


Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Posted on Monday April 08, 2024

On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa


Supernus Provides Regulatory Update for SPN-830
Posted on Monday April 08, 2024

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830. SPN-830 is an investigational apomorphine infusion device for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD) under U.S. Food and Drug Administration (FDA) review. The FD


Supernus to Participate in Two Upcoming Investor Conferences
Posted on Wednesday March 06, 2024

ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob


Stock Market & Investing Books

Enter a stock symbol to view the stock details.